3. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. *Blood*. 1996;87(3):1196-1198.

4. Passera R, Pollichieni S, Brunello L, et al. Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. *Biol Blood Marrow Transplant*. 2013;19(6):940-948.

5. Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. *Proc Natl Acad Sci USA*. 2002;99(20):13009-13013.

6. Rosenblatt J, Avivi I, Vasir B, et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. *Clin Cancer Res*. 2013;19(13):3640-3648.

7. Noonan KA, Huff CA, Davis J, et al. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. *Sci Transl Med*. 2015;7(288):288ra78.

8. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. *Nat Med*. 2015;21(8):914-921.

9. Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. *Blood*. 2015;125(20):3049-3058.

10. Murray ME, Gavile CM, Nair JR, et al. CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. *Blood*. 2014;123(24):3770-3779.

● ● ● **THROMBOSIS AND HEMOSTASIS**

Comment on Zhu et al, page 1494

Polyphosphates rock! A role in thrombosis?

Dougald M. Monroe UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

In this issue of *Blood*, Zhu et al have established, in human blood, that factor XIa and polyphosphate make significant contributions to thrombus formation.[1] This makes these molecules good targets for therapeutic intervention.

The emphasis on human blood is important, as many thrombosis studies have been conducted in mice. Mouse studies take advantage of 2 things: (1) robust imaging tools that allow in vivo thrombus formation to be monitored and quantified, and (2) genetic manipulation of the mice to generate mechanistic information. However, there are data to suggest that mice may have significant differences in thrombus formation relative to primates and humans.[2] Thus, it is critical to test potential antithrombotic mechanisms in human blood.

Directed antithrombotics in current use are targeted inhibitors of thrombin and factor Xa. However, Zhu et al went in a different direction and studied the role of factor XI. Factor XI is an especially interesting molecule, because it lies at the critical junction of the classical contact pathway (factor XIIa and high-molecular-weight kininogen activation of factor XI) and the platelet-driven thrombin feedback amplification loop. This feedback was suggested by studies showing that sulfated glycans could promote thrombin activation

of factor XI.[3,4] Subsequent work provided a physiological basis by showing that activated platelets could sustain this reaction.[5,6] The laboratory of Dr Morrissey established the mechanism of this activation by showing that polyphosphate released from platelet-dense granules was the agent that promoted thrombin activation of factor XI.[7]

A logical extension of those studies on the biochemistry of polyphosphate is to examine the antithrombotic properties of agents that target factor XI and polyphosphate. In this study, Zhu et al used sophisticated flow models of thrombosis to generate nuanced results.[1] They used whole blood to incorporate the critical contribution of platelets. They included the role of flow by passing the blood over collagen to give platelet adherence and contact activation. They studied the results of 3 inhibitors: (1) an antibody that selectively blocks factor XIIa activation of factor XI (without interfering with thrombin activation of factor XI), (2) an antibody that blocks factor XIa activation of factor IX, and (3) a compound that binds and neutralizes

A broad overview of the components that are subject to inhibition under 3 sets of conditions (many of the coagulation steps are omitted). For an accurate analysis, see supplemental Figure 6 in the article by Zhu et al that begins on page 1494. Platelets adhere to collagen and are partially activated releasing polyphosphate from dense granules (dark spots on the platelets). During fibrin formation, fibrin structure is altered by association with polyphosphate, leading to a structure that is more resistant to lysis. (A) Factor XII is activated to factor XIIa. Factor XIIa activates factor XI to factor XIa, which activates factor IX to factor IXa, leading to thrombin (IIa) generation and fibrin formation. (B) Tissue factor initiates the generation of a small amount of thrombin (IIa) that binds to polyphosphate and activates factor XI to factor XIa. Additional factor XIa is generated from factor XIIa formed by contact activation. Factor XIa activates factor IX to factor IXa, leading to thrombin (IIa) generation and fibrin formation. (C) At high tissue factor, sufficient factor IX is activated to factor IXa to drive thrombin (IIa) generation and fibrin formation. polyP, polyphosphate; TF, tissue factor.

polyphosphate (see figure). With these 3 inhibitors, they used low, medium, and high tissue factor to modulate the procoagulant signal. The study is complicated by the fact that merely drawing blood can result in nonphysiological contact activation. Zhu et al get around this by using a small amount of an inhibitor of factor XIIa. This allows them to suppress background effects while continuing to measure the contribution of factor XII and the contact pathway.

Unsurprisingly, in the absence of tissue factor, platelet surface factor IX activation was purely driven by contact factors. Similarly, at high tissue factor, sufficient factor IXa was generated by a tissue factor reaction in which the contribution of contact factor was less significant. At intermediate TF levels, the inhibitors of factor XI activation and activity slowed thrombus formation and reduced thrombus size. This effect was not related to platelet accumulation into the thrombus but

was specific for thrombin generation and fibrin formation.

Perhaps more interesting, Zhu et al showed that polyphosphate played a role in more than just thrombin generation through feedback activation of factor XI. Polyphosphate directly interacted with fibrin in a way that made the thrombus less susceptible to lysis by fibrinolytic agents. Blocking polyphosphate reduced thrombus stability and increased lysis of the fibrin clot. All of this suggests that polyphosphate is an intriguing target for antithrombotic agents. Such an antithrombotic would not only reduce thrombin generation but also alter fibrin structure to promote lysis of any thrombus that does form.

One of the holy grails of antithrombotic therapy is to have agents that are effective without increasing the risk of bleeding. Zhu et al discuss the data suggesting that the contribution of the contact pathway to hemostasis is to augment the existing platelet-driven thrombin generation. In this study, Zhu et al significantly advance our understanding of possible contributions of the contact pathway to thrombus formation. If, as this study suggests, factor XI and polyphosphate have a greater contribution to thrombus formation than hemostasis in human blood, then those molecules make appealing targets for novel antithrombotic agents.

Conflict-of-interest disclosure: The author declares no competing financial interests. ■

REFERENCES

1. Zhu S, Travers RJ, Morrissey JH, Diamond SL. FXIa and platelet polyphosphate as therapeutic targets during human blood clotting on collagen/tissue factor surfaces under flow. *Blood*. 2015;126(12):1494-1502.

2. Gailani D, Bane CE, Gruber A. Factor XI and contact activation as targets for antithrombotic therapy. *J Thromb Haemost*. 2015;13(8):1383-1395.

3. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. *J Biol Chem*. 1991;266(12):7353-7358.

4. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. *Science*. 1991;253(5022):909-912.

5. Oliver JA, Monroe DM, Roberts HR, Hoffman M. Thrombin activates factor XI on activated platelets in the absence of factor XII. *Arterioscler Thromb Vasc Biol*. 1999;19(1):170-177.

6. Kravtsov DV, Matafonov A, Tucker EI, et al. Factor XI contributes to thrombin generation in the absence of factor XII. *Blood*. 2009;114(2):452-458.

7. Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. *Blood*. 2011;118(26):6963-6970.

Does GVHD make amateurs out of professional APCs?

Alan M. Hanash   MEMORIAL SLOAN KETTERING CANCER CENTER

In this issue of *Blood*, Wikstrom and colleagues highlight antigen–presenting cell (APC) dysfunction as a potential cause of impaired antiviral immunity in graft-versus-host disease (GVHD).[1]

Along with malignant relapse and GVHD, posttransplant immunodeficiency and infections represent major barriers to successful allogeneic hematopoietic transplantation. Cytomegalovirus (CMV) infection in particular is a frequent cause of morbidity posttransplant, especially for recipients of T-cell–depleted and umbilical cord blood allografts as well as patients with GVHD.[2,3] GVHD is often viewed as a central problem because it necessitates treatment with corticosteroids and can also lead to thymic damage, both of which compromise immune recovery and may increase the risks of infection and relapse.[4-6]

Although impaired antimicrobial T-cell immunity posttransplant is frequently attributed to reduced T-cell recovery, competent adaptive immune responses require several steps, including T-cell activation by APCs such as dendritic cells (DCs). Moreover, there is a growing awareness that other immune cells besides αβ T cells contribute to anti-CMV immunity posttransplant, and the pathophysiology of CMV reactivation involves more than just T-cell deficiency.[7] Furthermore, in addition to impaired T-cell immune reconstitution, patients at risk for CMV infection due to GVHD have also been found to demonstrate reduced DC reconstitution, and CMV infection itself can impair DC function.[8,9]

To evaluate the function of DCs during viral infection posttransplant, Wikstrom and colleagues turned to experimental mouse models of bone marrow transplantation (BMT), which have proven to be tremendously valuable to the field of hematopoietic transplantation since its inception. First, the authors discovered that allogeneic BMT recipients with GVHD were profoundly more susceptible to infection with murine CMV (MCMV) posttransplant than syngeneic BMT recipients, and MCMV-infected mice with GVHD demonstrated more severe hepatic necrosis than uninfected mice with GVHD or infected mice without GVHD. The authors also found that there was reduced expansion of MCMV-reactive CD8 T cells in syngeneic transplant recipients after DC depletion, demonstrating the importance of DCs for generating an anti-MCMV immune response post-BMT.

Evaluating MCMV-reactive T cells after allogeneic BMT, the authors found that GVHD appeared to have an effect similar to DC depletion after syngeneic BMT. There was reduced expansion of MCMV-reactive CD8 T cells in allogeneic transplant recipients with GVHD. There were also fewer splenic CD8α$^+$ and CD11b$^+$ DCs in infected mice with GVHD, the splenic DCs that were present in mice with GVHD were less likely to be infected with MCMV, and these DCs demonstrated reduced expression of the costimulatory molecules CD40 and CD86. These defects could be overcome by transfer of MCMV-specific transgenic T cells or by transfer of polyclonal T cells from donor mice that had been exposed to MCMV.

The findings of the authors highlight the importance of DC function for mounting effective antiviral T-cell responses posttransplant. Interestingly, although MCMV-specific transgenic T cells appeared to expand less in mice with GVHD, they remained effective in controlling the virus. These were naive T cells, suggesting that APC-related defects posttransplant can be overcome if there is an adequate MCMV-reactive T-cell pool. However, this APC